Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N° 59.382. Prospecto vigente aprobado por ANMAT (ver código QR).
Giangrande P. Karim F. Nemes L, et al. long-term safety and efficacy of N8 GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2.J Thromb Hoemost. 2020;18(1):5 14.
Lentz SR. Kavalk.i K. Klamroth R, et al. Turoctocog alpha pegol (N8 GP) in severe hemophilia A: long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study. Res Proct Thromb Haemost 2022;6(2):e12674.
Saulyte Trakymiene s. Economou M. Kc net G, Landorph A. Shen C, Kearney S. Long•term safety and efficacy of NS GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5.J Thromb Haemost. 2020;18(suppl 1):15 25.
Giangrande P. Andreeva T, Chowdary P. et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A Thromb Haemost. 2017;117(2):252 261.
Meunier S. Alamelu J. Ehrenforth S. et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol. N8 GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117:1705• 1713.